HQ Team
January 30, 2023: Sun Pharmaceuticals announced it had acquired three brands from Aksigen to treat postoperative inflammation in patients undergoing minor surgery and dental procedures.
Disperzyme, disperzyme-CD and phlogam from Aksigen Hospital Care (“Aksigen”), of Mumbai-based healthcare company, Aksigen, were approved by the Drugs Controller General of India.
It hit the Indian market in 2013. Sun Pharmaceuticals did not disclose the amount paid for the deal.
Disperzyme and phlogam are the first enzyme-bioflavonoid combination of trypsin, bromelain and rutoside (TBR) to complete a clinical study in India and get DCGI approval, according to a company statement.
Systemic enzyme therapy
“This systemic enzyme therapy combination is being used to control edema, and it speeds up the healing process,” Kirti Ganorkar, CEO-India business, Sun Pharma, said.
“In a comparative clinical trial in India, the brands provided significantly better control and resolution of postoperative pain and inflammation. The addition of disperzyme and phlogam further strengthens our anti-inflammatory portfolio.”
The overall market of proteolytic enzymes for healing, pain and edema in India is around INR 5,000 million, according to a recent study by market research company IQVIA.
Improved healing
TBR, the systemic enzyme therapy, intervenes in different processes. First is the release of inflammatory mediators, the modulation of adhesion molecules, and the activation of fibrinolysis, consequently improving healing.
The company assessed the safety and efficacy of a fixed dose combination of trypsin, bromelain and rutoside through disperzyme and phlogam versus serratiopeptidase in 303 subjects with postoperative inflammation undergoing minor surgery and dental procedures.
According to the statement, the study demonstrated systemic enzyme therapy with a trypsinbromelain-rutoside combination provided significantly better control and resolution of postoperative pain and inflammation than serratiopeptidase.
Sun Pharma is the world’s fourth-largest speciality generic pharmaceutical company and one of India’s top pharmaceutical companies. Manufacturing facilities across six continents support the company’s global presence.
10.7% CAGR growth
According to Mordor Intelligence, India’s pharmaceuticals industry is expected to register a CAGR of 10.70% over the forecast period (2022-2027).
Indian pharma companies offer products in segments such as generic drugs, over-the-counter (OTC) medicines, active pharmaceutical ingredients (APIs), vaccines, contract research and manufacturing, and biosimilar and biologics.
In 2021 according to the Indian Brand Equity Foundation Report, in the case of generics, India accounts for 20% of global exports, and for the period 2021-22, the export of drugs and pharma products stood at $24.6 billion compared to $ 24.44 billion as of 2020-21.
The Indian pharmaceutical market is fragmented, with many companies operating globally and regionally.
They include Cipla Inc., Dr. Reddy’s Laboratories, Lupin, Sun Pharmaceutical Industries, Cadila Pharmaceuticals, GlaxoSmithKline plc, Biocon, Pfizer, Novartis AG, Merck & Co., Torrent Pharma, Divi’s Laboratories, Aurobindo Pharma Limited, Mankind Pharma, and Abbott India.
